改良森田治疗对慢性精神分裂症患者自知力和临床疗效的影响

The influence of modified Morita therapy on insight and clinical efficacy of chronic schizophrenic

目的探讨改良森田治疗对慢性精神分裂症患者自知力和临床疗效的影响。方法将60例慢性精神分裂症患者随机分为两组，每组30例，两组均接受常规抗精神病药物治疗、常规工娱疗及护理，研究组在此基础上联合改良森田治疗，观察6周。于治疗前及治疗6周末采用自知力与治疗态度问卷评定自知力状况，阳性与阴性症状量表评定临床疗效。结果治疗6周末，研究组自知力与治疗态度问卷评分较治疗前显著提高（P〈0．01），阳性与阴性症状量表评分较治疗前显著下降（P〈0．01），对照组自知力与治疗态度问卷及阳性与阴性症状量表评分均无明显变化（P〉0．05）；治疗前两组评分比较差异均无显著性（P〉0．05），治疗后研究组自知力与治疗态度问卷评分显著高于对照组（P〈0．01），阳性与阴性症状量表评分显著低于对照组（P〈0．05）。结论改良森田治疗能促进慢性精神分裂症患者自知力的恢复，提高治疗依从性和临床疗效。

Objective To explore the influenee of modified Morita therapy （MMT） on insight and clinical efficacy of chronic schizophrenic. Methods .Sixty patients with chronic schizophrenia were randomly divided into two groups of 30 ones each, both grdups received routine antipsychotic treatment, work and recreation therapy and nursing, research group was plus MMT for 6 weeks. Insight states were assessed with the Insight and Treatment Attitude Questionnaire （ITAQ） and effieacies with the Positive and Negative Syndrome Scale （PANSS） at baseline and at the end of the 6th week. Results At the end of the 6th week insight and ITAQ score increased more significantly （P〈0.01） and PANSS score lowered （P〈0.01） in research group, there were obvious changes in insight, ITAQ and PANSS score in control group （P 0.05） ; there were no significant group differences in scores at baseline （P〈0.05）, after treatment insight and ITAQ score were significantly higher （P〈0.01） and PANSS score lower （P〈0.05） in research than in control group. Conclusion MMT could promote recovery of insight of chronic schizophrenia and improve treatment compliance and efficacy.